52328-98-0
52328-98-0 結(jié)構(gòu)式
基本信息
二甲基姜黃素
ASC-J9 生產(chǎn)廠家
二甲基姜黃素, ≥95%
Dimethylcurcumin
Dimethylcurcumin, ≥95%
(1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one
1,4,6-Heptatrien-3-one, 1,7-bis(3,4-diMethoxyphenyl)-5-hydroxy-,(1E,4Z,6E)-
(1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one (ASC-J9)
Dimethylcurcumin【(1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one】
物理化學(xué)性質(zhì)
ANTIOXIDANT
ANTI-SEBUM
HAIR CONDITIONING
COLORANT
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/07/06 | S6630 | 二甲基姜黃素 Dimethylcurcumin (ASC-J9) | 52328-98-0 | 5mg | 1670.91元 |
| 2026/07/06 | S6630 | 二甲基姜黃素 Dimethylcurcumin (ASC-J9) | 52328-98-0 | 25mg | 5170.9元 |
| 2026/06/05 | HY-15194R | 二甲基姜黃素 Dimethylcurcumin (Standard) | 52328-98-0 | 5 mg | 740元 |
常見問題列表
| Target | Value |
|
AR
() |
Dimethylcurcumin (ASC-J9) is able to degrade fAR and AR3 in a dose-dependent manner in various human PCa cells. Dimethylcurcumin (ASC-J9) can also effectively suppress AR-targeted genes in CWR22Rv1-fARKD cells. Dimethylcurcumin (ASC-J9) (5 or 10 μM) significantly suppresses the DHT-induced cell growth in all three PCa cell lines. Dimethylcurcumin (ASC-J9) suppresses AR-targeted genes and cell growth by degradation of fAR and ectopic AR3 in C81 and C4-2 cells. Dimethylcurcumin (ASC-J9) selectively promotes AR degradation by disrupting the interaction between AR and AR coregulators. ASC-J9 reduces the AR aggregated AR-112Q in cells. Dimethylcurcumin (ASC-J9) suppresses the aggregation of AR-112Q in SBMA PC12/AR-112Q cells.
Dimethylcurcumin (ASC-J9) (75 mg/kg, i.p.) degrades both fAR and AR3 in the xenografted tumors in vivo, and SC-J9-treated tumors has significantly decreased Ki67-positive cells. Dimethylcurcumin (ASC-J9) (50 mg/kg every 48 h, i.p.) substantially ameliorates the SBMA symptoms in AR-97Q mice, and ameliorates neuromuscular pathological findings. The Dimethylcurcumin (ASC-J9)-treated SBMA mice have relatively normal serum testosterone concentrations. ASC-J9-treated mice show significantly smaller prostate tumor sizes when compared with those receiving classic ADT/castration with little serum androgen.